A randomized double-blind placebo-controlled trial of autologous platelet-rich plasma intradermal injections for the treatment of vulvar lichen sclerosus - 16/05/19
Funding sources: Supported by the Gynecologic Cancers Research Foundation, a Maryland 501(c)3 non-profit corporation. Supplies for this study were provided by Isto Biologics. |
|
Disclosure: Dr Goldstein is on the board of directors of the Gynecologic Cancers Research Foundation; he serves on advisory boards of Strategic Science and Technologies, Grunenthal, Ipsen, and Amag, and he receives research funding from Strategic Science and Technologies, Grunenthal, Ipsen, Endoceutics, The Gynecologic Cancers Research Foundation, Cellular Medicine Association, and ELeN. Ms Govind, Ms Mitchell, and Dr Heller have no conflicts of interest to disclose. |
|
Dr Goldstein was responsible for the study design, data collection, interpretation of data, and article preparation. Ms Govind was responsible for data collection, statistical analysis, interpretation of data, and article preparation. Ms Mitchell was responsible for data collection, interpretation of data, and article preparation. Dr Heller was responsible for data collection and article preparation. |
Vol 80 - N° 6
P. 1788-1789 - juin 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?